Using Low-dose Radiation Therapy to Propagate Systemic Response to in Situ Vaccines
Author | : Peter Michael Carlson |
Publisher | : |
Total Pages | : 0 |
Release | : 2020 |
Genre | : |
ISBN | : |
Download Using Low-dose Radiation Therapy to Propagate Systemic Response to in Situ Vaccines Book in PDF, ePub and Kindle
Despite substantial improvement in clinical cancer care, disease progression still occurs. The Sondel lab has developed a combination in situ vaccine (ISV) immunotherapy approach consisting of 12Gy local external beam radiation (RT) and intratumoral injections of hu14.18-IL2 immunocytokine (IC, a fusion of an anti-GD2 monoclonal antibody and IL-2) for treatment of GD2+ tumors. This ISV approach can render up to 70% of mice bearing a single B78 melanoma flank tumor disease-free, with tumor-specific systemic memory, but is insufficient to control distant, untreated tumors in models of multiple B78 implanted tumors. The goal of this thesis was to characterize the efficacy of using low-dose radiation (both RT and molecular targeted radionuclide therapy [TRT, [90]Y-NM600]) delivered to all sites of disease in enabling a systemic antitumor response following RT/IC ISV. Many shared resource cytometry facilities do not permit analysis of radioactive tissue for safety and radioactive waste disposal concerns. By investigating introduction of a cryopreservation step in the flow cytometry workflow, I demonstrated that cryopreservation of dissociated tumor and spleen cells after all staining and fixation gave results most concordant with non-cryopreserved cells, which allowed for analyses of radioactive TRT-treated tumors. In addition, I characterized a discrepancy in treatment outcome among mice implanted with B78 tumors treated with ISV. I determined that tumors implanted subcutaneously display a 'fixed' phenotype and are less likely to respond to RT/IC ISV. Conversely, tumors implanted intradermally are 'mobile' in phenotype and respond well to RT/IC ISV. After controlling for implantation depth, I determined that RT/IC ISV delivered to a primary B78 melanoma combined with either RT or [90]Y-NM600 TRT to secondary tumors resulted in greater antitumor effect compared to either RT/IC alone or radiation alone, as demonstrated by overall survival, and analysis of tumor growth rates. These data suggest that additional radiation to all disease sites is indeed capable of improving response to RT/IC ISV at distant sites. Ongoing studies are using flow cytometry and cytokine quantification to characterize the nature of the immune response to ISV at distant tumors, with and without additional radiation.